Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Engineering chemokines to develop optimized HIV inhibitors.

Oliver Hartley1, Robin E Offord

  • 1Department of Structural Biology and Bioinformatics, Centre Médical Universitaire, 1 rue Michel Servet, 1211 Geneva 4, Switzerland. oliver.hartley@medecine.unige.ch

Current Protein & Peptide Science
|June 25, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CCL3 is produced by aged neutrophils across cancers and promotes tumor growth.

Cancer cell·2026
Same author

Noncanonical roles of chemokine regions in CCR9 activation revealed by structural modeling and mutational mapping.

Nature communications·2025
Same author

Towards Context-Rich Automated Biodiversity Assessments: Deriving AI-Powered Insights from Camera Trap Data.

Sensors (Basel, Switzerland)·2025
Same author

Author Correction: Arylsulfatases and neuraminidases modulate engagement of CCR5 by chemokines by removing key electrostatic interactions.

Scientific reports·2024
Same author

Arylsulfatases and neuraminidases modulate engagement of CCR5 by chemokines by removing key electrostatic interactions.

Scientific reports·2024
Same author

Influenza A virus exploits transferrin receptor recycling to enter host cells.

Proceedings of the National Academy of Sciences of the United States of America·2023
Same journal

Exploring Neurological Disorder Therapeutics: The Progress and Future Prospects of Proteins and Peptides Derived from Blue Foods.

Current protein & peptide science·2026
Same journal

Significance of Proteomics in Cancer: Current Approaches and Trends in Biomarker Discovery.

Current protein & peptide science·2026
Same journal

Therapeutic Peptides as Targeting Vectors and Smart Therapeutics: Emerging Trends and Future Perspectives.

Current protein & peptide science·2026
Same journal

Innovative Protein Nanostructures and Hybrid Systems for Enhanced Encapsulation and Controlled Delivery of Bioactive Agents.

Current protein & peptide science·2026
Same journal

Nanotherapeutic Interventions in Diabetic Wound Healing: Biomarker- Guided Mechanisms and Translational Prospects.

Current protein & peptide science·2026
Same journal

Recent developments in intein-mediated protein splicing and their applications in bioengineering.

Current protein & peptide science·2026
See all related articles

Researchers are developing novel anti-HIV molecules by engineering chemokine ligands. Understanding chemokine structure-activity relationships and receptor interactions is key to creating potent HIV inhibitors for clinical use.

Area of Science:

  • Virology
  • Immunology
  • Medicinal Chemistry

Background:

  • Human Immunodeficiency Virus (HIV) entry into target cells relies on chemokine receptors.
  • Chemokines and their receptors play a crucial role in HIV pathogenesis.
  • Significant research has focused on chemokine structure-activity relationships since the early 1990s.

Purpose of the Study:

  • To review current knowledge on chemokine structure-activity relationships and receptor biology relevant to anti-HIV drug development.
  • To highlight engineered chemokine analogues with potent anti-HIV activity.
  • To discuss challenges and strategies for clinical development of these molecules.

Main Methods:

  • Literature review of chemokine structure-activity relationships and receptor interactions.

Related Experiment Videos

  • Analysis of mechanisms underlying chemokine inhibitory activity against HIV.
  • Examination of rational drug design and phage display strategies for identifying anti-HIV chemokine variants.

    • Main Results:

    • Detailed understanding of chemokine structure-activity relationships guides the design of anti-HIV analogues.
    • Engineered chemokine variants demonstrate potent anti-HIV activity.
    • Phage display facilitates isolation of effective chemokine-based HIV inhibitors.

    Conclusions:

    • Chemokine-based molecules offer a promising avenue for anti-HIV therapeutic development.
    • Further molecular engineering is necessary to overcome challenges for clinical application.
    • Continued research into chemokine biology and analogue design is crucial for advancing HIV treatment.